Subscribe to thousands of academic journals for just $40/month
Read and share the articles you need for your research, all in one place.

In Search of Better Prognostic Indicators for Patients with Oligodendrogliomas

Cancer Investigation , Volume 14 (3) – Jan 1, 1996

Details

Publisher
Informa UK Ltd
Copyright
© 1996 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted
Subject
Editorial Article
ISSN
0735-7907
eISSN
1532-4192
D.O.I.
10.3109/07357909609012152
Publisher site
See Article on Publisher Site

Preview Only

Expand Tray Hide Tray

In Search of Better Prognostic Indicators for Patients with Oligodendrogliomas

Abstract

Cancer Investigation, 14(3), 288-289 (1996) In Search o Better Prognostic Indicators for f Patients with Oligodendrogliomas E. G.Shaw, M.D. Departmentof Radiation Oncology Bowman Gray School of Medicine Winston-Salem,North Carohna27157 In this issue of Cancer Investigation, Peterson and Cairncross comprehensively review the epidemiology, clinical presentation, pathology, treatment, failure patterns, and prognosis of cerebral oligodendrogliomas.They describe a number of known diagnostic, pathological, and treatment-associated prognostic factors, including age, imaging-based contrast enhancement, extent of surgical resection, tumor grade, and the addition of radiation therapy and chemotherapy. In the current “molecular era” of medicine, what are the potential contributions of translational research to the diagnosis and treatment of oligodendrogliomas? Basic science investigations of these tumors have included assessments of ploidy, proliferation, and genetic factors. DNA content has no significant association with survival. Aneuploid oligodendrogliomashave comparable survival rates as diploid tumors (1-3). Proliferation,on the otherhand, as measured by the %S-. %G2M-,or %S+G2Mphase fractions, does significantly correlate with survival. In a study from the Mayo Clinic, the median survival time and 5-year survival rate were 9.5 years and 73%, respectively, in patients with an S-phase fraction of <6%, compared to 3.9 years and 39% for those with a 26% S-phase fraction. Coons et al.
Loading next page...

Preview Only. This article cannot be rented because we do not currently have permission from the publisher.

 
/lp/informa-healthcare/in-search-of-better-prognostic-indicators-for-patients-with-Oijq0ErRGE